wire - news in brief


Category



Results 301 - 350 of 355.


Health - Pharmacology - 23.10.2018
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig where other treatments have failed
The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed   Patients treated with Aimovig, reported significan

Pharmacology - Health - 22.10.2018
Roche’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemot

Pharmacology - Health - 22.10.2018
Novartis COMBI-AD study of Tafinlar + Mekinist continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit   Cure rate modeling which estimates fraction of patients

Health - Pharmacology - 21.10.2018
Roche’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
Entrectinib showed response irrespective of tumour type or spread to the central nervous system (CNS) Data will be submitted to global regulatory authorities, including the US Food and Drug Administr

Health - Pharmacology - 20.10.2018
Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer Tecentriq and nab -paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations Clinically meaningful overall survival improvement in the PD-L1-positive population at this interim analysis Data are being presented at the European Society for Medical Oncology (ESMO) 2

Health - Life Sciences - 19.10.2018
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer (NSCLC)   Clinical findings from ongoing study indicate safety prof

Health - 19.10.2018
Novartis announces presentation of new Lutathera NETTER-1 data
Novartis announces presentation of new Lutathera NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden Lutathera treatment was associated with a

Architecture - 19.10.2018
"Mediocre tools lead to mediocre thinking"
Architect Bernard Tschumi has donated the archives of his Bridge City project - developed for the City of Lausanne in 1988 - to EPFL.

Astronomy / Space Science - 18.10.2018

Health - Business / Economics - 18.10.2018

Health - 18.10.2018
One Health: Working together for human and animal health
Bern, 18.10.2018 - Prevention and early detection are central to effective control of communicable diseases and their vectors, such as mosquitoes.

Innovation / Technology - Computer Science / Telecom - 17.10.2018
Modifying a virtual environment in just a few clicks
Creating and modifying a virtual reality environment just got a lot easier thanks to software being released today by Imverse, an EPFL spin-off.

Event - Art and Design - 17.10.2018

Health - Life Sciences - 16.10.2018
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx leadership in spondyloarthritis
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) ,   In rheumatolo

Health - Pharmacology - 15.10.2018
Roche’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December Roche tod

Computer Science / Telecom - Law / Forensics - 11.10.2018
Joint research on Laser Deposition Welding
Joint research on Laser Deposition Welding
Empa and BeAM, a manufacturer of machines for metal 3D printing, are glad to announce an extensive research and development agreement.

Environment - 11.10.2018
Scientists head to Antarctica to study snow and icecaps
Scientists head to Antarctica to study snow and icecaps
EPFL scientists will soon be heading off to Antarctica, where they will spend four months collecting reams of meteorological data at Australia's Davis research station.

Health - Life Sciences - 10.10.2018
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya over Copaxone in patients with relapsing remitting multiple sclerosis
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg   Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial   Treatment discontinuations were overall more common in the

Computer Science / Telecom - Innovation / Technology - 10.10.2018

Health - 09.10.2018
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo   VOCs are the most common, painful complication of sickle cell disease and the main reas

Computer Science / Telecom - Innovation / Technology - 08.10.2018

Event - Careers / Employment - 08.10.2018

Innovation / Technology - 08.10.2018
Summit in the field of Additive Manufacturing
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).

Transport - 08.10.2018
Additive Manufacturing summit
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).

Health - Life Sciences - 08.10.2018
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d

Computer Science / Telecom - 08.10.2018

Innovation / Technology - Careers / Employment - 06.10.2018

Life Sciences - 05.10.2018
Congratulations to the FMI Prize winners 2018
As in previous years, several internal prizes were awarded during the FMI Annual Meeting, a 3 day scientific meeting attended by most scientists in the institute.

Business / Economics - 04.10.2018
Even Small Gifts Boost Business
The offering of a gift - a sign of gratitude for a good business relationship, or a bribe? It's a fine line that is often hard to judge.

Health - Pharmacology - 04.10.2018
Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
Baloxavir marboxil - a first-in-class, single-dose, investigational oral medicine - is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable to serious influenza complications CAPSTONE-2 showed that baloxavir marboxil significantly reduced time to improvement of influenza symptoms versus placebo Influenza, or ‘flu', results in millions of debilitating illnesse

Pharmacology - Health - 04.10.2018
FDA approves Roche’s Hemlibra for haemophilia A without factor VIII inhibitors
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based on an intra-patient comparison Only medicine that can be self-administered subcutaneously once we

Health - Innovation / Technology - 04.10.2018
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek broader

Health - Life Sciences - 03.10.2018
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones including sitting without support Preliminary data from Part 1 of the SUNFISH study show improvements in motor function in people with Type 2/3 SMA No drug-related safety findings leading to withdrawal in risdiplam

Earth Sciences - Social Sciences - 03.10.2018
Jacques Lévy wins the 2018 Vautrin-Lud Prize
Jacques Lévy wins the 2018 Vautrin-Lud Prize
Jacques Lévy has been awarded the 2018 Vautrin-Lud Prize, a geography award modeled on the Nobel Prize.

Health - 03.10.2018
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria   Agreement is part of Novartis strategy to partner with l

Innovation / Technology - Electroengineering - 02.10.2018
Cooperation in printed electronics
Cooperation in printed electronics
Empa is expanding its Coating Competence Center (CCC) thanks to a new partnership in the field of printed electronics with US-based equipment manufacturer Optomec.

Astronomy / Space Science - Chemistry - 28.09.2018
Two Years after Rosetta
Two Years after Rosetta
On September 30, 2016, the active phase of the ESA's Rosetta mission came to an end with the controlled crash landing of the probe on the surface of the comet Chury.

Life Sciences - 27.09.2018
Fructose metabolism and noncommunicable diseases: recent findings and new research perspectives
Prof. Luc Tappy, Department of Physiology Fructose is a physiological nutrient which, when consumed in excess, may have adverse metabolic effects, mainly in the liver (hepatic insulin resistance and fat storage).